Home › Marginal Zone Lymphoma › Ohio
Pag-aaral pangklinika para sa Marginal Zone Lymphoma sa Ohio
13 pag-aaral para sa Marginal Zone Lymphoma ang naghahanap ng mga kalahok sa mga site sa Ohio.
Mga Lungsod sa Ohio
Opisyal na teksto ng pag-aaral (English)
Epco, Zanu, Ritux for R/R FL or MZL
- The Ohio State University Wexner Medical Center, Columbus
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06563596Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Licking Memorial Hospital, Newark
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT04840602A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Cleveland Clinic, Cleveland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07101328Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07225439Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
Nagre-recruitPhase 1/2
Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06533579A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
- University of Cincinnati, Cincinnati
- The Ohio State University, Columbus
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT06708897A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Cincinnati Medical Center, Cincinnati
- Cleveland Clinic, Cleveland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT05131022Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
- Ohio Health Riverside Methodist Hospital, Columbus
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 22, 2026 · NCT05700149Study of SGR-1505 in Mature B-Cell Neoplasms
- Gabrail Cancer & Research Center, Canton
- The Ohio State University - The James Cancer Hospital, Columbus
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 13, 2026 · NCT05544019Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- University of Cincinnati, Cincinnati
- Ohio State University, Columbus
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 13, 2026 · NCT04775745AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Taylor Cancer Research Center, Maumee
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 10, 2025 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University Hospitals Cleveland Medical Center, Cleveland
- The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2025 · NCT05780034Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.